Elicera Therapeutics AB (publ) Year-End 1 January – 31 December 2025

Elicera reported Q4 operating loss SEK -7.13m and full-year operating loss SEK -17.94m, with a full-year net loss of SEK -17.41m, cash flow from operations SEK -21.55m and EPS of SEK -0.38; the board proposes no dividend. The company raised SEK 22.0m in March 2025 via exercised TO2 subscriptions and delivered positive clinical readouts—four of six patients in the lowest CARMA dose cohorts achieved complete metabolic responses—and ELC-100 received U.S. orphan drug designation with final Phase I/IIa data showing good safety and early efficacy. Management is pursuing financing for preclinical programs (notably ELC-401 targeting a possible 2027 clinical start), with a U.S. patent application for the iTANK platform still under review, making near-term funding the primary investor risk.

Analysis

Contrarian angles: The market likely underweights licensing upside and ELC‑100 orphan designation value — early academic validation and a Nature Biomed Eng. proof point support >€50M upfront licensing potential if next cohort confirms activity. The market may be overpricing financing/dilution risk if management secures staged partnerships rather than straight equity raises; conversely the common historical parallel (small CAR‑T biotechs) shows small datasets can either trigger M&A or rapid dilution depending on timing. Watch for a licensing offer or partnership term sheet (threshold: ≥50 MSEK upfront or ≥€5–10M milestone triggers) — such an event should materially re-rate the equity.

Key Decisions for Investors

• Establish a 2–3% long position in Elicera Therapeutics (company-level equity) now as a disciplined event trade ahead of the Q2 2026 CARMA high‑dose update; set a hard stop‑loss at −40% and plan to add to 4–6% if the update shows ≥1 additional complete response and no new SAEs within 30 days of publication.
• Implement a 6–12 month bull call spread (if listed options exist) on Elicera: buy near‑ATM call expiring Dec‑2026 and sell a higher strike ~30–40% above current price to cap premium; if no options, buy equity and simultaneous 30–40% OTM protective puts expiring Dec‑2026 to limit dilution/clinical downside.
• Execute a pair trade: long Elicera 2% vs short XBI (ticker XBI) 1% or short SBIO 0.8% to neutralize sector beta until Q2 2026; unwind the short if biotech volatility falls <20% IV or after a positive licensing announcement.
• Set objective financing/partnership stop‑triggers: reduce position to zero if no announced financing or partnership providing ≥50 MSEK by 2026‑09‑30, or immediately exit on USPTO final adverse decision on core iTANK claims; increase allocation if a partnership/ upfront payment ≥50 MSEK (or ≥€5M) is announced.